title: Management and ultrasonographic appearance of infantile hypertrophic pyloric stenosis with intravenous atropine sulfate.
abstract: Some infants with hypertrophic pyloric stenosis (HPS) have responded to oral atropine treatment. To achieve sufficient effect of atropine, it must be administered intravenously (i.v.). Therefore, with ultrasonography, we studied the changes in the pyloric muscle in HPS during and after intravenous administration of atropine. Twenty-three infants were studied. Atropine sulfate was initially administered at a dose of 0.04 mg/kg day i.v., and the dose was increased by 0.01 mg/kg/day until vomiting ceased. When vomiting ceased after administration of intravenous atropine sulfate, the infants received oral atropine sulfate at twice the effective intravenous dose; this was continued for 2 weeks. Ultrasonography was repeated until pyloric muscles normalized. Twenty-two infants were free from vomiting after 1-8 days of intravenous atropine sulfate (dosages of 0.04-0.11 mg/kg/day). In 21 infants, weight gain continued after atropine treatment even though no change in thickness of the pyloric muscles was demonstrated ultrasonographically. Only 2 infants required pyloromyotomy because of prolonged treatment or a mistake in underdosing of oral atropine. All of the 21 infants who recovered after intravenous atropine without surgery had normalization of pyloric muscle caliber, as shown by ultrasonography 4-12 months after treatment. Atropine is an effective medicine for HPS. Regression of pyloric thickening after vomiting has been controlled implies that pyloric muscle hypertrophy could be worsened by the spasm that occurs in HPS.
authors.affiliation: Department of Pediatrics, Osaka Medical College, Japan.
authors.forename: A
authors.initials: A
authors.lastname: Nagita
authors.forename: J
authors.initials: J
authors.lastname: Yamaguchi
authors.forename: K
authors.initials: K
authors.lastname: Amemoto
authors.forename: A
authors.initials: A
authors.lastname: Yoden
authors.forename: T
authors.initials: T
authors.lastname: Yamazaki
authors.forename: M
authors.initials: M
authors.lastname: Mino
mesh_terms: D000284:Administration, Oral; D001285:Atropine / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006984:Hypertrophy; D007223:Infant; D007275:Injections, Intravenous; D008297:Male; D009130:Muscle, Smooth / Q000187:drug effects*; D011707:Pyloric Stenosis / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D012044:Regression Analysis; D014839:Vomiting / Q000188:drug therapy* / Q000209:etiology
chemical_list: D001285:Atropine